Compounded vs Branded GLP-1s: What’s Legal in 2026

As of 2026, mass-produced compounded GLP-1s are being phased out of the United States market. The legal mechanism that allowed them, a drug’s presence on the FDA shortage list, no longer applies to semaglutide or tirzepatide, and the agency is moving to block the remaining route through which outsourcing facilities could resume bulk production.

Two compounding pathways exist under the Federal Food, Drug, and Cosmetic Act. Section 503A covers state-licensed pharmacies making patient-specific preparations, and section 503B covers FDA-registered outsourcing facilities producing larger batches. Both may copy an approved drug only in limited circumstances, the most important of which is when the drug is in shortage. With the shortages resolved, copying semaglutide or tirzepatide is now treated as making an unlawful copy of an available product.

The 503B outsourcing-facility category itself exists because of a public-health disaster. Congress created it in the Drug Quality and Security Act of 2013, after contaminated steroid injections from the New England Compounding Center triggered a nationwide fungal meningitis outbreak that killed dozens and sickened hundreds. The framework was designed to bring large-scale compounding under federal oversight, which is the same authority the FDA is now using to constrain bulk GLP-1 production.

The bottom line: compounded GLP-1s were a shortage-era workaround, and with the shortages over the legal basis for producing them at scale has been removed.

Date	Event
2022	Semaglutide and tirzepatide added to the FDA shortage list, opening legal compounding
Oct 2024	FDA declares the tirzepatide shortage resolved
Feb 2025	FDA declares the semaglutide shortage resolved
Feb-Mar 2025	Enforcement discretion for tirzepatide ends: 503A on 18 Feb, 503B on 19 Mar
7 May 2025	A federal district court upholds the FDA in Outsourcing Facilities Association v. FDA; ruling is appealed to the Fifth Circuit
Through 2025	More than 50 FDA warning letters issued to compounders and telehealth distributors
Mar 2026	Fifth Circuit hears oral argument on the appeal; decision pending
30 Apr 2026	FDA proposes removing semaglutide, tirzepatide and liraglutide from the 503B bulks list
1 May 2026	Proposal published in the Federal Register, docket 2026-08552
30 Jun 2026	Public comment deadline on the 503B bulks proposal

The 30 April 2026 proposal, published in the Federal Register on 1 May under docket 2026-08552, would exclude the three drugs from the 503B bulks list on a finding of no clinical need. The agency is taking public comment through 30 June 2026 before issuing a final determination, and industry analysts expect a final rule by the third quarter of 2026.

One nuance is worth noting. Liraglutide injection remains on the shortage list as of the proposal, so it can still be compounded by 503B facilities for now, even though it is named in the bulks-list exclusion. Once that shortage clears, removal from the bulks list would close its pathway too.

The legal fight runs in parallel to the rulemaking. The Outsourcing Facilities Association, joined by the compounder FarmaKeio, sued the FDA over its decision that the tirzepatide shortage was resolved, arguing the determination was arbitrary and capricious under the Administrative Procedure Act. The case has become the central test of how far the FDA’s shortage authority reaches.

District court ruling

In the Northern District of Texas, Judge Mark Pittman first denied the association’s request for a preliminary injunction, then on 7 May 2025 upheld the FDA’s position, leaving the agency free to enforce against compounded copies while the case proceeded. The ruling was read as confirming the FDA’s authority over shortage determinations.

Fifth Circuit appeal

The plaintiffs appealed to the Fifth Circuit Court of Appeals, which heard oral argument in March 2026. A central thread was procedural: whether the FDA, in effectively deciding the rights of compounders through a shortage determination rather than formal notice-and-comment rulemaking, had short-circuited the process the law requires. The court has not yet ruled, so the enforcement posture stands but the underlying question remains open.

The bottom line: a federal court has upheld the FDA so far, the Fifth Circuit appeal is unresolved, and a separate final rule could close the door regardless of how the appeal lands.

The distinction between branded and compounded GLP-1s is now a distinction between an FDA-approved product and an unapproved copy. Branded semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are manufactured to approved standards with verified dose and purity. Compounded versions are not FDA-approved or individually reviewed for safety and efficacy.

The FDA has explicitly rejected affordability and insurance access as grounds for continued compounding, holding that cost does not constitute a clinical need. In parallel, the manufacturers have introduced direct cash-pay channels that have narrowed the price gap that drove compounding demand in the first place.

The shrinking price gap

Compounded GLP-1s undercut branded list prices that once exceeded $1,000 a month. That gap is closing. Branded list prices still sit high, with Wegovy around $1,349 a month, but direct-to-consumer cash pricing for lower-dose Zepbound has fallen to roughly $1,086, and newer approved options price far lower still. The oral small-molecule orforglipron (Foundayo) launched with LillyDirect self-pay from $149 a month, a figure that sits inside the range compounded products used to occupy. As approved supply expands and cash prices fall, the affordability argument for compounding weakens further.

The safety record

Safety concerns have driven much of the enforcement. The FDA has logged more than 455 adverse-event reports for compounded semaglutide and more than 320 for compounded tirzepatide, alongside dosing errors with multidose vials, some serious enough to require hospitalisation, plus sterility-related recalls and a parallel counterfeit market. These are not abstract risks; they are documented harms tied to non-standardised products.

The telehealth dimension

Much of the compounded GLP-1 boom ran through telehealth platforms and cash-pay weight-loss clinics that paired a quick online consultation with a compounded prescription. As the legal basis narrows, those businesses face a forced transition. Through 2025 the FDA sent more than 50 warning letters to compounders and telemedicine operators, including notices challenging marketing that implied a compounded product was equivalent to the approved drug. Large players such as Hims, Ro and LifeMD have had to pivot their GLP-1 offerings as the compounding window closes.

The research-use-only grey market

Separately from compounding, semaglutide and tirzepatide are widely sold as “research use only” powders. This is a legally distinct framework intended for laboratory study, not human use, and it is not affected by the 503B compounding restrictions. Buying these compounds and self-administering them is neither compounding nor a prescription, and it sits outside the safeguards of both. For how to assess any such supply, see our guide on reading a certificate of analysis.

The bottom line: the FDA treats cost as irrelevant to compounding eligibility, and the branded products are now the only versions backed by verified manufacturing and regulatory review.

Mass compounding of GLP-1s is largely a United States phenomenon, a product of the shortage-list mechanism in US law. The branded versions of semaglutide and tirzepatide are sold under the same names internationally (Ozempic, Wegovy, Mounjaro, Zepbound), but the United Kingdom and Australia restrict these molecules to licensed prescription products and do not operate an equivalent large-scale compounding allowance, so the branded-versus-compounded debate is far less prominent in those markets. For the wider legal position, see our pages on whether peptides are legal in the US, UK and Australia.

• The final 503B bulks rule, expected in the third quarter of 2026, which would permanently foreclose bulk compounding even if a future shortage were declared.
• The pending Fifth Circuit decision in Outsourcing Facilities Association v. FDA, the last significant legal challenge to the agency’s shortage authority.
• Whether liraglutide leaves the shortage list, which would close its remaining 503B pathway.
• New oral options such as orforglipron, which expand approved supply and further weaken the case for compounding.
• Enforcement against counterfeit and illicit “research” supply as compounded access narrows.

Is compounded semaglutide still legal in 2026?

Large-scale compounding is no longer legal because the semaglutide shortage was resolved in February 2025; only limited patient-specific 503A compounding remains, and the FDA has proposed closing the 503B bulk pathway entirely.

Why is the FDA restricting compounded GLP-1s?

The shortages that legally permitted compounding have ended, and the FDA has cited more than 775 combined adverse-event reports for compounded semaglutide and tirzepatide, dosing errors and counterfeits as reasons to act.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Ozempic and Wegovy are FDA-approved branded semaglutide with verified dose and purity, whereas compounded semaglutide is an unapproved copy that is not individually reviewed for safety or efficacy.

Does the FDA accept cost as a reason to allow compounding?

No. The FDA has explicitly stated that affordability and insurance access do not constitute a clinical need that would justify compounding an available approved drug.

What happens to patients currently using compounded GLP-1s?

As access narrows, patients are generally moving to branded products through cash-pay channels or insurance, or to newer approved options, and should plan any switch with a prescriber rather than turning to unregulated research-use-only supply.